AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

AstraZeneca’s record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer: Cambridge, UK Thursday, May ...

Anglo-Swedish pharma major AstraZeneca reports that it will have a historic presence at this year’s American Society of ...

Visa, AstraZeneca, Shell, Ocean Power Technologies and Wheeler Real Estate Investment Trust are part of the Zacks top Analyst ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in non-muscle invasive bladder cancer (NMIBC). Top-line results from ...

AstraZeneca’s hopes of positioning its PD-L1 inhibitor Imfinzi as a post-surgery therapy for people with earlier-stage lung cancer have taken a knock, although it performed well in a bladder ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...